The adult sermorelin literature is mostly physiology probes. The two studies most often cited for aging tested a norleucine analog, not sermorelin, and the best-known adult framing is an editorial with no abstract.

CJC-1295 and ipamorelin are sold as a pair. PubMed returns ten records mentioning both, all reviews, and no human study of the combination. What the closest related evidence actually shows.

Tesamorelin is a modified GHRH analog studied almost entirely in HIV-associated lipodystrophy, where a licensed product has a Phase 3 record. What the research covers, where it stops, and what the mechanism annotation says.

Tesamorelin and sermorelin are both GHRH analogs, but one is the full 44-residue hormone with a stabilizing cap and the other is a 29-residue fragment. Verified identity, half-life, regulatory and trial records, side by side.

The tesamorelin liver-fat record is one 61-patient trial in people with HIV, published in Lancet HIV 2019 with the word “might”, and at least six later papers that re-analyze the same patients. How re-analysis inflates a lane.

Tesamorelin and ipamorelin act on two different receptors and are sold together as a blend. The published record contains zero studies of the two compounds combined; the six papers that mention both are reviews.

The tesamorelin cognition record: a 2012 trial in 152 older adults reported a favorable effect, never replicated; a 2025 Phase 2 trial and a 2026 pilot were both null. What each study found, in its own words.